These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 9885468)

  • 1. The measurement of indirect costs in the health economics evaluation literature. A review.
    Jacobs P; Fassbender K
    Int J Technol Assess Health Care; 1998; 14(4):799-808. PubMed ID: 9885468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A literature review of indirect costs associated with stroke.
    Joo H; George MG; Fang J; Wang G
    J Stroke Cerebrovasc Dis; 2014 Aug; 23(7):1753-63. PubMed ID: 24957313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telemedicine for the Medicare population: pediatric, obstetric, and clinician-indirect home interventions.
    Hersh WR; Wallace JA; Patterson PK; Shapiro SE; Kraemer DF; Eilers GM; Chan BK; Greenlick MR; Helfand M
    Evid Rep Technol Assess (Summ); 2001 Aug; (24 Suppl):1-32. PubMed ID: 11569328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of the literature on the economics of noncompliance. Room for methodological improvement.
    Cleemput I; Kesteloot K; DeGeest S
    Health Policy; 2002 Jan; 59(1):65-94. PubMed ID: 11786175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The direct and indirect costs associated with endometriosis: a systematic literature review.
    Soliman AM; Yang H; Du EX; Kelley C; Winkel C
    Hum Reprod; 2016 Apr; 31(4):712-22. PubMed ID: 26851604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct, indirect and intangible costs of acute hand and wrist injuries: A systematic review.
    Robinson LS; Sarkies M; Brown T; O'Brien L
    Injury; 2016 Dec; 47(12):2614-2626. PubMed ID: 27751502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measurement of indirect costs for people with vision impairment.
    Chou SL; Misajon R; Gallo J; Keeffe JE
    Clin Exp Ophthalmol; 2003 Aug; 31(4):336-40. PubMed ID: 12880460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cost of lost productivity in pharmacoeconomics analysis. Part I. A systematic review of the literature].
    Wrona W; Hermanowski T; Golicki D; Jakubczyk M; Macioch T; Goszczyńska K; Wójcik R
    Przegl Epidemiol; 2011; 65(1):147-52. PubMed ID: 21735852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Empirical standard costs for health economic evaluation in Germany -- a proposal by the working group methods in health economic evaluation].
    Krauth C; Hessel F; Hansmeier T; Wasem J; Seitz R; Schweikert B
    Gesundheitswesen; 2005 Oct; 67(10):736-46. PubMed ID: 16235143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluations and randomized trials in spinal disorders: principles and methods.
    Korthals-de Bos I; van Tulder M; van Dieten H; Bouter L
    Spine (Phila Pa 1976); 2004 Feb; 29(4):442-8. PubMed ID: 15094541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic value of out-of-hospital emergency care: a structured literature review.
    Lerner EB; Maio RF; Garrison HG; Spaite DW; Nichol G
    Ann Emerg Med; 2006 Jun; 47(6):515-24. PubMed ID: 16713777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The direct and indirect costs of uterine fibroid tumors: a systematic review of the literature between 2000 and 2013.
    Soliman AM; Yang H; Du EX; Kelkar SS; Winkel C
    Am J Obstet Gynecol; 2015 Aug; 213(2):141-60. PubMed ID: 25771213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Indirect costs in health technology assessment].
    Jakubczyk M; Wrona W; Macioch T; Golicki D; Niewada M; Hermanowski T
    Pol Merkur Lekarski; 2010 Jan; 28(163):42-5. PubMed ID: 20369723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic analysis in dermatology.
    Ellis CN; Reiter KL; Wheeler JR; Fendrick AM
    J Am Acad Dermatol; 2002 Feb; 46(2):271-83. PubMed ID: 11807441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cost of lost productivity in pharmacoeconomics analysis. Part II. Survey in the expert group].
    Wrona W; Hermanowski T; Jakubczyk M; Golicki D; Czech M; Niewada M; Kolasa K
    Przegl Epidemiol; 2011; 65(1):153-7. PubMed ID: 21735853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economics of medically unexplained symptoms: a systematic review of the literature.
    Konnopka A; Schaefert R; Heinrich S; Kaufmann C; Luppa M; Herzog W; König HH
    Psychother Psychosom; 2012; 81(5):265-75. PubMed ID: 22832397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-of-illness studies of diabetes mellitus: a systematic review.
    Ng CS; Lee JY; Toh MP; Ko Y
    Diabetes Res Clin Pract; 2014 Aug; 105(2):151-63. PubMed ID: 24814877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-of-illness studies in systemic lupus erythematosus: A systematic review.
    Zhu TY; Tam LS; Li EK
    Arthritis Care Res (Hoboken); 2011 May; 63(5):751-60. PubMed ID: 21557530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costs of illness in cost-effectiveness analysis. A review of the methodology.
    Hodgson TA
    Pharmacoeconomics; 1994 Dec; 6(6):536-52. PubMed ID: 10155283
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.